You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

71 search results for: patient burden

Chronic Spontaneous Urticaria (CSU) Interactive <b>Patient</b> Case
interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

Dermatology
Learn more about the guideline-based diagnosis of chronic spontaneous urticaria with this interactive patient case.
View more
On-Treatment Clinical Remission in Asthma <b>Patient</b>s Case Tool
interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

Pulmonology
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.
View more
Connecting the Dots from Type 2 Inflammation to <b>Patient</b> Perspectives
expert video

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

Type 2 Inflammation
Learn the connection between chronic type 2 inflammation, symptoms, and impact on quality of life in diseases with underlying type 2 inflammation
View more
Comorbidities and Disease <b>Burden</b> in CSU
expert video

Comorbidities and Disease Burden in CSU

Dermatology
In their interview Drs. Maurer and Ensina shed light on the significant burden of comorbidities in CSU.
View more
Early Intervention in AD: Latest Clinical and Real-world Data
expert video

Early Intervention in AD: Latest Clinical and Real-world Data

Dermatology
Highlights from ESPD 2023 ADVENT: Reviewing the current treatment landscape and the potential for early intervention in pediatric atopic dermatitis.
View more
Targeting Type 2 Inflammation: ​Skin Barrier Normalization​
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Dermatology
Highlights from ESPD 2023 ADVENT: Uncovering how type 2 inflammation influences skin barrier dysfunction in atopic dermatitis.
View more
High <b>Burden</b> of Atopic Dermatitis in Children
expert video

High Burden of Atopic Dermatitis in Children

Dermatology
Explore the debilitating effects that impact day-to-day functioning in pediatric patients with atopic dermatitis – a short soundbite from EADV 2022.
View more
AD, PN, and CSU: Distinct, Pruritic Diseases
expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

Dermatology
Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.
View more
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Dermatology
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
View more
Type 2 Inflammation Underpins Pediatric Severe Asthma
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Pulmonology
Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.
View more
Differences in Itch in AD, PN, and CSU
expert video

Differences in Itch in AD, PN, and CSU

Dermatology
Dr. Shawn Kwatra reviews the distinct characteristics of itch, and the associated patient burden in AD, PN, and CSU.
View more
Skin Dyspigmentation In Prurigo Nodularis (PN)
interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

Dermatology
This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region